00:17 , Feb 16, 2019 |  BioCentury  |  Finance

Andera looks early for cancer immunotherapy

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
10:22 , Jul 6, 2018 |  BioCentury  |  Finance

Dynacure’s quick transfer

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
13:45 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Rothschild becomes Andera after employee, partner buyout

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...
19:29 , Apr 6, 2018 |  BC Extra  |  Financial News

Partners, employees buy out Rothschilds' stake in EdRIP

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...
16:03 , Mar 15, 2018 |  BC Extra  |  Company News

Arbor launches with $15.6 million, new CRISPR enzyme

Arbor Biotechnologies Inc. (Cambridge, Mass.) emerged from stealth mode on Thursday with a study detailing the discovery of a new CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and a $15.6 million series A round that closed...
23:09 , Feb 6, 2018 |  BC Extra  |  Financial News

EdRIP unveils new €345 million fund

Edmond de Rothschild Investment Partners closed its fifth fund, BioDiscovery 5, at €345 million ($428 million), one of the largest European VC funds focused on life sciences ever, according to BioCentury’s BCIQ database. The fund...
23:05 , Feb 6, 2018 |  BioCentury  |  Finance

Stepping up in Europe

After closing one of Europe’s largest ever life sciences VC funds, Edmond de Rothschild Investment Partners now has the firepower to follow portfolio companies longer and put more capital to work in a wider variety...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Financial News

GamaMabs Pharma completes venture financing

GamaMabs Pharma S.A. , Toulouse, France   Business: Cancer, Antibodies   Date completed: 2015-12-15   Type: Venture financing   Raised: EUR15 million ($16.4 million)   Investors: BioDiscovery 4; InnoBio Fund; IRDINov; Alto Invest; iXO Private...